Loading
A phase 2 trial of nivolumab and ipilimumab in colorectal cancer, run by Fudan University, not yet recruiting.
Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07403877 by Fudan University, with a registry enrolment figure of 114 participants, started 2026-02-01 and due to reach its primary completion in 2031-12-31. Interventions recorded: Nivolumab; Ipilimumab (1mg/kg); PULSAR; Radical surgery; Watch & wait. Conditions listed: Colorectal Cancer (MSI-H). Primary outcome: Complete regression (CR) rate. Colorectal eligibility wording from the registry: "Histopathologically confirmed primary colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Ipilimumab, Nivolumab, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Nivolumab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Nivolumab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Nivolumab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Ipilimumab, Nivolumab, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Nivolumab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.